Revise to specify that the study focused on women aged 50-60 with osteopenic bone density.
Background
Fragility fractures are prevalent among women without osteoporosis, highlighting the need for effective preventive strategies. Current treatments have shown inconsistent results in this demographic, necessitating further investigation into therapies like zoledronate. This study addresses a critical gap by evaluating the efficacy of zoledronate in reducing fracture risk among younger postmenopausal women.
Data Highlights
Group
New Vertebral Fractures (%)
Relative Risk (RR)
Zoledronate-Placebo
6.6
0.59 (95% CI 0.36 to 0.97)
Placebo-Placebo
11.1
-
Key Findings
6.6% of women in the zoledronate-placebo group experienced new vertebral fractures.
The relative risk of fractures was reduced to 0.59 compared to the placebo group.
The number needed to treat to prevent one fracture was 22 over 10 years.
Both zoledronate treatment groups showed improved bone density at 5 and 10 years.
Adverse events were low, with no atypical femur fractures or osteonecrosis of the jaw reported.
Clinical Implications
The findings support the use of zoledronate as a preventive measure for vertebral fractures in younger postmenopausal women, even in the absence of osteoporosis. Clinicians should consider this treatment option for patients at risk of fractures despite normal or osteopenic bone density.
Conclusion
Zoledronate administration effectively reduces vertebral fracture incidence in younger postmenopausal women, suggesting a potential shift in fracture prevention strategies for this population.
